

UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/973,424	10/09/2001	Sudhirdas K. Prayaga	15866-585CIP2 (Cura-85CIP)

CONFIRMATION NO. 8925

FORMALITIES LETTER



OC00000007728388

Ivor R. Elrifi, Ph.D., Esq.
 MINTZ, LEVIN, COHN, FERRIS,
 GLOVSKY and POPEO, P.C.
 One Financial Center
 Boston, MA 02111

Done By	
<input checked="" type="checkbox"/> Data Entry	<i>TLW</i>
<input checked="" type="checkbox"/> Docket Entry	<i>5/27/02</i>
<input type="checkbox"/> Docket Cross Off	
<input type="checkbox"/> Previously Entered	
<input type="checkbox"/> No Docketing Req	
<input type="checkbox"/> ELITE	
<input type="checkbox"/> Annuities	

Date Mailed: 03/27/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail patin21help@uspto.gov or patin3help@uspto.gov

RECEIVED

APR 01 2002

MINTZ LEVIN, BOSTON
PATENT DOCKET DEPT.

A copy of this notice **MUST** be returned with the reply.

dehus
 Customer Service Center

Initial Patent Examination Division (703) 308-1202


PART 2 - COPY TO BE RETURNED WITH RESPONSE

 RECEIVED
 MAY 03 2002
 TECH CENTER 1600/2900

04-26-02
Box 851 1653
Express Mail Label No.: EL955089259US

Date of Deposit: April 25, 2002

Attorney Docket No. 15966-585 CIP2 (Cura-85 CIP2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 03 2002
TECH CENTER 1600/2900

APPLICANTS: Prayaga *et al.*

SERIAL NUMBER: 09/973,424

EXAMINER: Not Yet Assigned

FILING DATE: October 9, 2001

ART UNIT: 1653

FOR: NOVEL POLYPEPTIDES HOMOLOGOUS TO THYMOSIN, EPHRIN A RECEPTORS, AND FIBROMODULIN, AND POLYNUCLEOTIDES ENCODING SAME

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

In response to the March 27, 2002 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, transmitted herewith for filing in the present application are the following documents:

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg.);
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (13 pgs.);
3. Computer Readable Form (1 disk);
4. Sequence Listing (59 pgs.);
5. Statement in Support of Computer Readable Form (1 pg.);
6. Supplemental Preliminary Amendment (3 pgs.); and
7. Return Postcard.

Applicants believe no fees are due in this filing, however, if any fee is due, the Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311, Reference No. 15966-585CIP2 (Cura-85CIP2).

Respectfully submitted,

April 25, 2002



30623

PATENT TRADEMARK OFFICE

Naomi S. Biswas
Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Express Mail Label No.: E1955089259US

Date of Deposit: April 25, 2002

Attorney Docket No. 15966-585 CIP2 (Cura-85 CIP2)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga *et al.*

SERIAL NUMBER: 09/973,424

EXAMINER: Not Yet Assigned

FILING DATE: October 9, 2001

ART UNIT: 1653

FOR: NOVEL POLYPEPTIDES HOMOLOGOUS TO THYMOSIN, EPHRIN A RECEPTORS, AND FIBROMODULIN, AND POLYNUCLEOTIDES ENCODING SAME

RECEIVED
MAY 03 2002
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES


In response to the Notice to Comply with Sequence Listing Requirements, mailed March 27, 2002, in the above mention application, Applicants submit a copy of the Notice to Comply, a substitute copy of the Sequence Listing (59 pages), a substitute computer readable form (CRF) of the Sequence Listing, a Supplemental Preliminary Amendment, and a statement that the content of the paper and computer readable copies are the same.

Applicants believe no fees are due in this filing, however, if any fee is due, the Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311, Reference No. 15966-585CIP2 (Cura-85CIP2).

The Examiner is encouraged to call the undersigned below with any questions or comments related to this filing.

Respectfully submitted,

April 25, 2002


Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241